The HLA-A*31:01 allele: influence on carbamazepine treatment
Vincent Lai Ming Yip,1,2 Munir Pirmohamed1,2 1MRC Centre for Drug Safety Science, Institute of Translational Medicine, Department of Molecular and Clinical Pharmacology, University of Liverpool, 2Department of Clinical Pharmacology,The Royal Liverpool and Broadgreen University Hospital NHS Trust, Li...
Saved in:
Main Authors: | Yip VLM (Author), Pirmohamed M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomics Testing Confirmation of Carbamazepine Induced DRESS Reaction of an HLA-A*31:01 Positive, Polypharmacy Patient
by: Leigh Speicher, et al.
Published: (2021) -
Characterization of a novel HLA-A*11:335 allele resulting from a rare interlocus recombination involving HLA-A*11:01:01:01/126 and HLA-H*02:07/14/18 alleles with nanopore sequencing, in a volunteer from the China Marrow Donor Program
by: Li-Qun Zhang, et al.
Published: (2022) -
Single Nucleotide Variants as Proxies for HLA-A*31:01 in Native American Populations
by: Vanessa Câmara Fernandes, et al.
Published: (2022) -
The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
by: Gwendolin S. Simper, et al.
Published: (2019) -
Prevalence of HLA-B*57:01 allele in HIV-positive and HIV-negative population of eastern India: An epidemiological study
by: Abhilasha Gautam, et al.
Published: (2022)